GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CEL-SCI Corp (STU:LSRM) » Definitions » Cyclically Adjusted Price-to-FCF

CEL-SCI (STU:LSRM) Cyclically Adjusted Price-to-FCF : (As of May. 30, 2024)


View and export this data going back to 2007. Start your Free Trial

What is CEL-SCI Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


CEL-SCI Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for CEL-SCI's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CEL-SCI Cyclically Adjusted Price-to-FCF Chart

CEL-SCI Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CEL-SCI Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CEL-SCI's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, CEL-SCI's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CEL-SCI's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CEL-SCI's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where CEL-SCI's Cyclically Adjusted Price-to-FCF falls into.



CEL-SCI Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

CEL-SCI's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, CEL-SCI's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=-0.08/131.7762*131.7762
=-0.080

Current CPI (Mar. 2024) = 131.7762.

CEL-SCI Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201406 -1.727 100.560 -2.263
201409 -1.691 100.428 -2.219
201412 -1.510 99.070 -2.009
201503 -2.084 99.621 -2.757
201506 -1.637 100.684 -2.143
201509 -1.231 100.392 -1.616
201512 -1.203 99.792 -1.589
201603 -0.943 100.470 -1.237
201606 -0.973 101.688 -1.261
201609 -1.137 101.861 -1.471
201612 -0.660 101.863 -0.854
201703 -0.381 102.862 -0.488
201706 -0.331 103.349 -0.422
201709 -0.293 104.136 -0.371
201712 -0.190 104.011 -0.241
201803 -0.200 105.290 -0.250
201806 -0.143 106.317 -0.177
201809 -0.150 106.507 -0.186
201812 -0.124 105.998 -0.154
201903 -0.115 107.251 -0.141
201906 -0.126 108.070 -0.154
201909 -0.103 108.329 -0.125
201912 -0.108 108.420 -0.131
202003 -0.114 108.902 -0.138
202006 -0.107 108.767 -0.130
202009 -0.104 109.815 -0.125
202012 -0.148 109.897 -0.177
202103 -0.177 111.754 -0.209
202106 -0.145 114.631 -0.167
202109 -0.103 115.734 -0.117
202112 -0.100 117.630 -0.112
202203 -0.069 121.301 -0.075
202206 -0.128 125.017 -0.135
202209 -0.115 125.227 -0.121
202212 -0.103 125.222 -0.108
202303 -0.162 127.348 -0.168
202306 -0.122 128.729 -0.125
202309 -0.102 129.860 -0.104
202312 -0.094 129.419 -0.096
202403 -0.080 131.776 -0.080

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


CEL-SCI  (STU:LSRM) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


CEL-SCI Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of CEL-SCI's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


CEL-SCI (STU:LSRM) Business Description

Industry
Traded in Other Exchanges
Address
8229 Boone Boulevard, Suite 802, Vienna, VA, USA, 22182
CEL-SCI Corp is a player in the biotechnology sector. It is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company is focused on activating the immune system to fight cancer and infectious diseases. It is focused on the development of Multikine (Leukocyte Interleukin, Injection), investigational immunotherapy under development for the treatment of certain head and neck cancers, and anal warts or cervical dysplasia.

CEL-SCI (STU:LSRM) Headlines

No Headlines